| Original language | English |
|---|---|
| Pages (from-to) | 851-854 |
| Number of pages | 4 |
| Journal | Journal of Asthma and Allergy |
| Volume | 15 |
| Early online date | 28 Jun 2022 |
| DOIs | |
| Publication status | E-pub ahead of print - 28 Jun 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Asthma and Allergy, Vol. 15, 28.06.2022, p. 851-854.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
AU - Hanania, Nicola A.
AU - Maspero, Jorge F.
AU - Halpin, David MG
AU - Jackson, David J.
AU - Panettieri, Reynold A.
AU - Castro, Mario
AU - Domingo, Christian
AU - Daizadeh, Nadia
AU - Gall, Rebecca
AU - Jacob-Nara, Juby A.
AU - Ortiz, Benjamin
AU - Djandji, Michel
AU - Rowe, Paul J.
AU - Deniz, Yamo
N1 - Funding Information: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02414854. Medical writing/editorial assistance was provided by Natalia Crespo, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline. Funding Information: Nicole A Hanania has received research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline; and reports consultancy for Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Teva. Jorge F Maspero is a consultant for AstraZeneca, Sanofi, Teva; has received speaker fees from GlaxoSmithKline, Inmunotek, Menarini, Novartis, Uriach; and research grants from Novartis. David MG Halpin reports advisory board and speaker fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis, Pfizer, Sandoz, Sanofi. David Jackson has received advisory board fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, Teva. Reynold A Panettieri is a consultant for AstraZeneca, Avillion, MedImmune, Bayer, Teva, RIFM, Equillium, Theravance Biopharma; and a speaker for AstraZeneca, Genentech, Regeneron Pharmaceuticals, Inc., Sanofi; has received research grants from ACTIV-1, Origo, NIH, Janssen, Vault Health, AstraZeneca, Equillium, Genentech, MedImmune, OncoArendi Therapeutics, RIFM. Mario Castro reports research support from American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, Sanofi-Aventis, Shionogi; is a consultant for Genentech, Novartis, Sanofi-Aventis, Teva; has received speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi, Teva, Merck and Amgen; and royalties from Elsevier. Christian Domingo has received travel and speaker fees from ALK, Allergy Therapeutics, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GlaxoSmithKline, HAL Allergy, Inmunotek, Menarini, Novartis, Pfizer, Sanofi-Aventis, Stallergenes Greer, Takeda, Teva. Nadia Daizadeh is a former Sanofi employee and may hold stock and/or stock options in the company. Juby A Jacob-Nara, Michel Djandji, Paul J Rowe are Sanofi employees and may hold stock and/or stock options in the company. Rebecca Gall, Benjamin Ortiz, Yamo Deniz are employees and shareholders of Regeneron Pharmaceuticals, Inc. Rebecca Gall also reports non-financial support from Excerpta Medica. The authors report no other conflicts of interest in this work.
PY - 2022/6/28
Y1 - 2022/6/28
UR - http://www.scopus.com/inward/record.url?scp=85134655921&partnerID=8YFLogxK
U2 - 10.2147/JAA.S354013
DO - 10.2147/JAA.S354013
M3 - Letter
AN - SCOPUS:85134655921
SN - 1178-6965
VL - 15
SP - 851
EP - 854
JO - Journal of Asthma and Allergy
JF - Journal of Asthma and Allergy
ER -